Advanced search
Publication Cover
Expert Review of Obstetrics & Gynecology Volume 8, 2013 - Issue 2
Journal homepage
16
Views
0
CrossRef citations to date
0
Altmetric
Review

Systemic treatment for recurrent epithelial ovarian cancer

Whay Kuang Chia The Royal Marsden NHS Foundation Trust, Gynaecology Unit, Downs Road, Sutton, Surrey, SM2 5PT, UK; National Cancer Centre, 11 Hospital Drive, 169610 Singapore; The Royal Marsden NHS Foundation Trust, Gynaecology Unit, Downs Road, Sutton, Surrey, SM2 5PT, UK; National Cancer Centre, 11 Hospital Drive, 169610 Singapore
,
Angela George The Royal Marsden NHS Foundation Trust, Gynaecology Unit, Downs Road, Sutton, Surrey, SM2 5PT, UK; The Royal Marsden NHS Foundation Trust, Gynaecology Unit, Downs Road, Sutton, Surrey, SM2 5PT, UK
&
Susana Banerjee The Royal Marsden NHS Foundation Trust, Gynaecology Unit, Downs Road, Sutton, Surrey, SM2 5PT, UK; The Royal Marsden NHS Foundation Trust, Gynaecology Unit, Downs Road, Sutton, Surrey, SM2 5PT, UK. [email protected]
Pages 161-168 | Published online: 10 Jan 2014

References

  • Pujade-Lauraine E, Paraiso D, Cure H. Predicting the effectiveness of chemotherapy (CX) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc. Am. Soc. Clin. Oncol. 21, Abstract 829 (2002).
  • Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in Phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of Phase II trials. Br. J. Cancer 59(4), 650–653 (1989).
  • Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9(3), 389–393 (1991).
  • Friedlander M, Trimble E, Tinker A et al.; Gynecologic Cancer InterGroup. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 21(4), 771–775 (2011).
  • Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat. Curr. Oncol. Rep. 13(6), 459–471 (2011).
  • Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol. Oncol. 108(1), 53–57 (2008).
  • Rustin GJ, van der Burg ME, Griffin CL et al.; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376(9747), 1155–1163 (2010).
  • Parmar MK, Ledermann JA, Colombo N et al.; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375), 2099–2106 (2003).
  • Pfisterer J, Plante M, Vergote I et al.; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24(29), 4699–4707 (2006).
  • Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28(20), 3323–3329 (2010).
  • Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or Fallopian tube cancer. J. Clin. Oncol. 30(17), 2039–2045 (2012).
  • Cavalli F, Kaye SB, Hansen HH. Textbook of Medical Oncology. Kaye SB (Ed.). CRC Press, FL, USA (2009).
  • Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 Phase III randomized trial. Ann. Oncol. 22(1), 39–48 (2011).
  • Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol. Oncol. 94(1), 67–73 (2004).
  • Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 13(7), 1584–1588 (1995).
  • Ledermann JA, Gabra H, Jayson GC et al. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin. Cancer Res. 16(19), 4899–4905 (2010).
  • George A, Tunariu N, Wilkinson N et al. Efficacy of platinum plus gemcitabine (G) in platinum-resistant (R) compared to platinum-sensitive (S) ovarian cancer: the Royal Marsden experience. Ann. Onc. 23 (Suppl. 9), Abstract 972 (2012).
  • Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst. Rev. doi:10.1002/14651858.CD001034.pub2 (2010) (Epub ahead of print).
  • Smyth JF, Gourley C, Walker G et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res. 13(12), 3617–3622 (2007).
  • Pujade-Lauraine E, Hilpert F, Weber B et al. AURELIA: a randomized Phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (Pt)-resistant recurrent ovarian cancer (OC). J Clin. Oncol. 30 (Suppl. 18), Abstract 5002 (2012) .
  • The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609–615 (2011).
  • Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res. 72(11), 2701–2704 (2012).
  • Kuo KT, Mao TL, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 174(5), 1597–1601 (2009).
  • Anglesio MS, George J, Kulbe H et al.; Australian Ovarian Cancer Study Group. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin. Cancer Res. 17(8), 2538–2548 (2011).
  • Tan DS, Iravani M, McCluggage WG et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin. Cancer Res. 17(6), 1521–1534 (2011).
  • Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363(16), 1532–1543 (2010).
  • Mok SC, Bell DA, Knapp RC et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53(7), 1489–1492 (1993).
  • Auner V, Kriegshäuser G, Tong D et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9, 111 (2009).
  • Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34(3), 433–443 (2010).
  • Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur. J. Cancer 47(Suppl. 3), S116–S130 (2011).
  • Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, Fallopian tube, and peritoneal cancer. J. Clin. Oncol. 27(33), 5601–5606 (2009).
  • Friedlander M, Hancock KC, Rischin D et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol. Oncol. 119(1), 32–37 (2010).
  • Eichbaum M, Mayer C, Eickhoff R et al. The PACOVAR-trial: a Phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer 11, 453 (2011).
  • Hashimoto K, Man S, Xu P et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9(4), 996–1006 (2010).
  • Penson RT, Moore KN, Flemming GF et al. A Phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), Fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162). J. Clin. Oncol. 30(Suppl. 15), Abstract 5012 (2012).
  • Schilder RJ, Sill MW, Lee RB et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 26(20), 3418–3425 (2008).
  • Schilder RJ, Brady WE, Lankes HA et al. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 127(1), 70–74 (2012).
  • Matei D, Sill MW, Lankes HA et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J. Clin. Oncol. 29(1), 69–75 (2011).
  • Welch SA, Hirte HW, Elit L et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int. J. Gynecol. Cancer 20(5), 787–793 (2010).
  • Pölcher M, Eckhardt M, Coch C et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother. Pharmacol. 66(1), 203–207 (2010).
  • Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26(22), 3709–3714 (2008).
  • Baumann KH, du Bois A, Meier W et al. A Phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann. Oncol. 23(9), 2265–2271 (2012).
  • Biagi JJ, Oza AM, Chalchal HI et al. A Phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann. Oncol. 22(2), 335–340 (2011).
  • Karlan BY, Oza AM, Richardson GE et al. Randomized, double-blind, placebo-controlled Phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol. 30(4), 362–371 (2012).
  • Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer. Can. J. Physiol. Pharmacol. 88(6), 676–681 (2010).
  • Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336(20), 1401–1408 (1997).
  • Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56(1), 265–271 (1995).
  • Møller P, Hagen AI, Apold J et al. Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers. Eur. J. Cancer 43(11), 1713–1717 (2007).
  • Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J. Clin. Oncol. 20(6), 1480–1490 (2002).
  • Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917–921 (2005).
  • Patel KJ, Yu VP, Lee H et al. Involvement of BRCA2 in DNA repair. Mol. Cell 1(3), 347–357 (1998).
  • Carser JE, Quinn JE, Michie CO et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol. Oncol. 123(3), 492–498 (2011).
  • Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30(21), 2654–2663 (2012).
  • Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet. 204(10), 525–535 (2011).
  • Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl Acad. Sci. USA 108(8), 3406–3411 (2011).
  • Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26(22), 3785–3790 (2008).
  • Nijman SM. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 585(1), 1–6 (2011).
  • Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123–134 (2009).
  • Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28(15), 2512–2519 (2010).
  • Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737), 245–251 (2010).
  • Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12(9), 852–861 (2011).
  • Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366(15), 1382–1392 (2012).
  • Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat. Rev. Clin. Oncol. 7(9), 508–519 (2010).
  • Sawada K, Radjabi AR, Shinomiya N et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67(4), 1670–1679 (2007).
  • Buckanovich RJ, Berger R, Sella A et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 29(Suppl. 15), Abstract 5008 (2011).
  • Harb WA, Sessa C, Hirte HW et al. A Phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. J. Clin. Oncol. 29(Suppl. 15), Abstract 3099 (2011).
  • Naumann RW, Symanowski JT, Ghamande SA et al. PRECEDENT: a randomized Phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J. Clin. Oncol. 29(Suppl. 15), Abstract 5045 (2011) .
  • Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10(13), 4420–4426 (2004).
  • Teodoridis JM, Strathdee G, Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist. Updat. 7(4–5), 267–278 (2004).
  • Matei D, Shen C, Fang F et al. A Phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC). J. Clin. Oncol. 29(Suppl. 15), Abstract 5011 (2011).
  • Kelly MG, Mor G, Husband A et al. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, Fallopian tube, or primary peritoneal cancers. Int. J. Gynecol. Cancer 21(4), 633–639 (2011).
  • Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106(9), 1933–1939 (2006).
  • Harter P, du Bois A, Hahmann M et al.; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13(12), 1702–1710 (2006).
  • MarkmanM, Moon J, Wilczynski S et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) Phase 3 randomized trial.Gynecol. Oncol. 116(3), 323–325 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.